Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.17), $0.24 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $23 million versus the consensus estimate of $16 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.